Drug intelligence / Profile preview

etomidate + midazolam + sufentanil + cisatracurium + sevoflurane

Development stage
Unknown
Lead developer
China Medical University
Modality
Small Molecules
Administration
Intravenous, Inhalation
01

Overview

This general anesthetic regimen is a multi-drug combination protocol utilized by **China Medical University** in clinical research, specifically the GIM-POD study, to induce and maintain anesthesia in patients undergoing gastrointestinal surgery. The induction phase consists of **etomidate** (a carboxylated imidazole hypnotic), **midazolam** (a benzodiazepine), **sufentanil** (a potent opioid analgesic), and **cisatracurium** (a non-depolarizing neuromuscular blocking agent). Maintenance of anesthesia is achieved through the inhalation of **sevoflurane** (a halogenated ether) supplemented with continuous sufentanil administration. This combination is designed to provide a balanced state of hypnosis, amnesia, analgesia, and muscle relaxation while minimizing hemodynamic fluctuations during major surgical procedures.

Other names
General anesthetic regimen (China Medical University)GIM-POD anesthetic protocol
02

Targets

GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)BZD site (GABA-A receptor benzodiazepine site)NMDAR (Glutamate receptor ionotropic, NMDA)Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on etomidate + midazolam + sufentanil + cisatracurium + sevoflurane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on etomidate + midazolam + sufentanil + cisatracurium + sevoflurane.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call